Annual report

Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS
Revenue¥613.8bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥628.9bn2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥599.5bn2018-04-01 → 2019-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥117.3bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥116.0bn2021-04-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS
Profit before tax¥97.1bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥106.5bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥102.7bn2018-04-01 → 2019-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥77.3bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥85.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥79.5bn2018-04-01 → 2019-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.35Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.24Tat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.12Tat 2019-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥856.7bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥754.8bnat 2020-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥698.0bnat 2019-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥166.9bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥123.0bnat 2019-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥121.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥117.5bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥93.6bn2018-04-01 → 2019-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥85.3bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥84.7bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥74.8bn2018-04-01 → 2019-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.4bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥14.0bn2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥67.5bn2018-04-01 → 2019-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥102.332020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥113.962019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥108.72018-04-01 → 2019-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥102.112020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥112.612019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥104.972018-04-01 → 2019-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,492.15at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,338.46at 2022-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,133.13at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,003.36at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥939.6at 2019-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio63.4%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio60.8%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2019-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE9.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE11.7%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE12.7%2018-04-01 → 2019-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees30,207at 2023-03-31Cons.Number of employees
Employees28,294at 2022-03-31Cons.Number of employees
Employees26,482at 2021-03-31dCons.Number of employees
Employees26,438at 2020-03-31dCons.Number of employees
Employees25,378at 2019-03-31dCons.Number of employees
Revenue¥375.0bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥341.4bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥316.4bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥319.0bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥307.0bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Operating income¥67.8bn2022-04-01 → 2023-03-31StandaloneOperating income
Operating income¥59.4bn2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥91.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥79.4bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥65.3bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥80.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥72.9bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥99.7bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax¥78.8bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income¥79.0bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥62.8bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥52.0bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥65.3bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥58.1bn2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Total assets¥1.33Tat 2023-03-31StandaloneAssets
Total assets¥1.28Tat 2022-03-31StandaloneAssets
Total assets¥1.26Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.15Tat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.04Tat 2019-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥566.1bnat 2023-03-31StandaloneLiabilities
Total liabilities¥517.3bnat 2022-03-31StandaloneLiabilities
Net assets / equity¥765.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥765.4bnat 2022-03-31StandaloneNet assets
Net assets / equity¥725.2bnat 2021-03-31dStandaloneNet assets
Net assets / equity¥687.2bnat 2020-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥624.9bnat 2019-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥91.5bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥98.3bnat 2022-03-31StandaloneCash and deposits
EPS (basic)¥105.222022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥83.042021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.892020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥87.312019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥79.472018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥105.172022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥82.992021-04-01 → 2022-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥68.742020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥86.292019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥76.782018-04-01 → 2019-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥292020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥282019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥542018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,027.34at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,011.08at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥958.26at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥912.44at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥840.16at 2019-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio57.4%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.9%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE7.4%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.0%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.2%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued747,682,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued379,760,000at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,457at 2023-03-31StandaloneNumber of employees
Employees5,377at 2022-03-31StandaloneNumber of employees
Employees5,247at 2021-03-31dStandaloneNumber of employees
Employees5,087at 2020-03-31dStandaloneNumber of employees
Employees4,908at 2019-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2022-04-01 → 2023-03-31¥1.5bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2023-03-31¥243m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥142m
Blood And Cell Technologies Companyreportable segmentcapex2022-04-01 → 2023-03-31¥21.5bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2023-03-316908 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥147.6bn
Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥11.2bn
Cardiac And Vascular Companyreportable segmentcapex2022-04-01 → 2023-03-31¥31.9bn
Cardiac And Vascular Companyreportable segmentemployeesat 2023-03-3116060 pure
Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥480.6bn
Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥112.2bn
Medical Care Solutions Companyreportable segmentcapex2022-04-01 → 2023-03-31¥20.9bn
Medical Care Solutions Companyreportable segmentemployeesat 2023-03-316201 pure
Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥191.7bn
Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥14.8bn
—segment totalcapex2022-04-01 → 2023-03-31¥74.3bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥820.0bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥138.2bn
Reconciling Itemsreconcilingcapex2021-04-01 → 2022-03-31¥4.4bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2022-03-31¥251m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31−¥3.2bn
Blood And Cell Technologies Companyreportable segmentcapex2021-04-01 → 2022-03-31¥17.6bn
Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2022-03-31¥120.6bn
Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2022-03-31¥20.8bn
Cardiac And Vascular Companyreportable segmentcapex2021-04-01 → 2022-03-31¥32.0bn
Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2022-03-31¥397.1bn
Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2022-03-31¥93.2bn
Medical Care Solutions Companyreportable segmentcapex2021-04-01 → 2022-03-31¥15.3bn
Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2022-03-31¥185.3bn
Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2022-03-31¥23.6bn
—segment totalcapex2021-04-01 → 2022-03-31¥64.8bn
—segment totalrevenue external2021-04-01 → 2022-03-31¥703.1bn
—segment totalsegment profit2021-04-01 → 2022-03-31¥137.7bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2023-03-31249 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2023-03-311841 pure
Medical Care Solutions Companyreportable segmentemployeesat 2023-03-312375 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,773
ItemContextValueUnit
Other changes in working capital ope cf IFRSCurrentYearDuration-9845000000JPY
Subtotal ope cf IFRSPrior1YearDuration172236000000JPY
Subtotal ope cf IFRSCurrentYearDuration144287000000JPY
Interest and dividends received ope cf IFRSPrior1YearDuration1033000000JPY
Interest and dividends received ope cf IFRSCurrentYearDuration2276000000JPY
Interest paid ope cf IFRSPrior1YearDuration-1312000000JPY
Interest paid ope cf IFRSCurrentYearDuration-1372000000JPY
Income taxes refund paid ope cf IFRSPrior1YearDuration-30489000000JPY
Income taxes refund paid ope cf IFRSCurrentYearDuration-27655000000JPY
Net cash provided by used in operating activities IFRSPrior1YearDuration141467000000JPY
Net cash provided by used in operating activities IFRSCurrentYearDuration117536000000JPY
Payments into time deposits inv cf IFRSPrior1YearDuration-3000000JPY
Payments into time deposits inv cf IFRSCurrentYearDuration-242000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YearDuration7000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYearDuration1000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YearDuration-53515000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYearDuration-52697000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YearDuration26000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYearDuration510000000JPY
Purchase of intangible assets inv cf IFRSPrior1YearDuration-20590000000JPY
Purchase of intangible assets inv cf IFRSCurrentYearDuration-19476000000JPY
Purchase of marketable securities inv cf IFRSPrior1YearDuration-1705000000JPY
Purchase of marketable securities inv cf IFRSCurrentYearDuration-1361000000JPY
Proceeds from sale of marketable securities inv cf IFRSPrior1YearDuration180000000JPY
Proceeds from sale of marketable securities inv cf IFRSCurrentYearDuration5988000000JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YearDuration-2853000000JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYearDuration-142000000JPY
Proceeds from sale of businesses and other inv cf IFRSPrior1YearDuration-JPY
Proceeds from sale of businesses and other inv cf IFRSCurrentYearDuration8298000000JPY
Net cash provided by used in investing activities IFRSPrior1YearDuration-78454000000JPY
Net cash provided by used in investing activities IFRSCurrentYearDuration-59121000000JPY
Proceeds from short term borrowings fin cf IFRSPrior1YearDuration-JPY
Proceeds from short term borrowings fin cf IFRSCurrentYearDuration677000000JPY
Repayments of short term borrowings fin cf IFRSPrior1YearDuration-JPY
Repayments of short term borrowings fin cf IFRSCurrentYearDuration-677000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YearDuration-30670000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYearDuration-1242000000JPY
Redemption of bonds fin cf IFRSPrior1YearDuration-10000000000JPY
Redemption of bonds fin cf IFRSCurrentYearDuration-JPY
Repayments of lease obligations fin cf IFRSPrior1YearDuration-6750000000JPY
Repayments of lease obligations fin cf IFRSCurrentYearDuration-7331000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YearDuration-3000000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYearDuration-50085000000JPY
Dividends paid fin cf IFRSPrior1YearDuration-23455000000JPY
Dividends paid fin cf IFRSCurrentYearDuration-27900000000JPY
Net cash provided by used in financing activities IFRSPrior1YearDuration-70879000000JPY
Net cash provided by used in financing activities IFRSCurrentYearDuration-86559000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YearDuration12347000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYearDuration10215000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YearDuration4481000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2023-03-31pass
balance sheet identitynon_consolidated 2022-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass